ClinicalTrials.gg
RecruitingNCT07704580OPALSUpdated Oct 13, 2026

Phase 1b/2 Study of IV Sarilumab in Adult With RA

A Phase 1/2 interventional study of Sarilumab, SAR153191 SC and Sarilumab, SAR153191 IV in Rheumatoid Arthritis, sponsored by Sanofi. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 13, 20268 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Planned enrollment
8th of 22
140 · median 88
Started
2026
the only one that year
Phase 1/2
2 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 1/2, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a Phase 1/Phase 2 study with:

  • 5-arms design for Part A;
  • and a single arm for Part B.

The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in male and female participants with moderately to severely active rheumatoid arthritis aged 18 years of age or older.

Study details include:

  • The study duration will be up to 64 weeks.
  • The treatment duration will be up to 6 months for each study phase.
  • Part A has 10 visits, including a post-treatment end of study (EOS) follow-up visit.

    • For participants entering the open label extension to receive the approved 200 mg sarilumab every two weeks (Q2W) dose, there will be 3 additional study visits.
    • For the intra-study sarilumab 200 mg Q2W subcutaneous (SC) arm, participants will be evaluated over the course of 24 weeks plus post-treatment EOS follow-up visit following the schedule of activities (SoA) of Part A from Day -1 to Day 29 (total of 8 visits) and the SoA of Part B from Week 4 to Week 24 (total of 8 visits) and a post-treatment end of study (EOS) follow-up visit at Week 30 (Part B) for a total of 17 visits, including a post-treatment EOS follow-up visit.
  • Part B has 13 visits, including a post-treatment EOS follow-up visit.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years old or the legal age of consent in the jurisdiction in which the study is taking place or older, at the time of signing the .
  • Diagnosis of RA, according to the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2010 RA Classification Criteria with ≥3 months disease duration.
  • ACR Class I to III functional status, based on the 1991 revised criteria
  • Moderate-to-severely active RA, defined as: DAS28-ESR>3.2.
  • Inability to continue treatment with a RA DMARD approved for use because of intolerance or inadequate response.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Any prior (within the defined periods below) or concurrent use of :

    • Janus kinase (JAK) inhibitor (eg, tofacitinib) within 4 weeks of baseline.
    • Cell-depletion agents (eg, anti CD20) without evidence of recovery of B cells to baseline level.
    • Anakinra within 1 week of baseline.
    • Abatacept within 8 weeks of baseline.
    • Tumor necrosis factor (TNF) inhibitors within 2 to 8 weeks.
    • Alkylating agents including cyclophosphamide (CYC) within 6 months of baseline.
    • Cyclosporine (CsA), azathioprine (AZA) or mycophenolate mofetil (MMF) or leflunomide within 4 weeks of baseline.
  • Therapeutic failure, including inadequate response or intolerance, or , to biological IL-6 antagonist (prior IL-6 antagonist treatment that was terminated for reasons unrelated to therapeutic failure at least 3 months before baseline is not exclusionary).
  • Unstable methotrexate (MTX) dose (if participant is on concomitant MTX).
  • Concurrent use of systemic (CS) of more than 10 mg/day.
  • Pregnant or breastfeeding woman.
  • Exclusion related to tuberculosis (TB): active TB or a history of incompletely treated TB regardless of screening Quantiferon® result.
  • History of invasive opportunistic infections, including but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis despite resolution or John Cunningham virus (progressive multifocal leukoencephalopathy).
  • Uncontrolled diabetes mellitus.
  • History of prior articular or prosthetic joint infection.
  • Prior or current history of , including lymphoproliferative diseases, other than adequately-treated carcinoma in-situ of the cervix, non- squamous cell or basal cell carcinoma of the skin, within 5 years prior to the baseline visit.
  • History of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation.
  • History of juvenile idiopathic arthritis or arthritis onset prior to age 16.
  • Severe systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Sarilumab 200 mg Q2W SC - Part A

    Participants will receive Sarilumab 200 mg Q2W SC on Day 1 every 2 weeks for 24 weeks.

    Drug: Sarilumab, SAR153191 SC

  • Experimental
    Sarilumab Dose Level 1 (DL1) IV - Part A

    Participants will receive Sarilumab DL1 IV. Participants continuing in the open label extension (OLE) arm will receive Sarilumab 200 mg SC Q2W for an additional 20 weeks.

    Drug: Sarilumab, SAR153191 SC · Drug: Sarilumab, SAR153191 IV

  • Experimental
    Sarilumab Dose Level 2 (DL2) IV - Part A

    Participants will receive Sarilumab DL2 IV. Participants continuing in the open label extension (OLE) arm will receive Sarilumab 200 mg SC Q2W for an additional 20 weeks.

    Drug: Sarilumab, SAR153191 SC · Drug: Sarilumab, SAR153191 IV

  • Experimental
    Sarilumab Dose Level 3 (DL3) IV - Part A

    Participants will receive Sarilumab DL3 IV. Participants continuing in the open label extension (OLE) arm will receive Sarilumab 200 mg SC Q2W for an additional 20 weeks.

    Drug: Sarilumab, SAR153191 SC · Drug: Sarilumab, SAR153191 IV

  • Experimental
    Sarilumab Dose Level 4 (DL4) IV - Part A

    Participants will receive Sarilumab DL4 IV. Participants continuing in the open label extension (OLE) arm will receive Sarilumab 200 mg SC Q2W for an additional 20 weeks.

    Drug: Sarilumab, SAR153191 SC · Drug: Sarilumab, SAR153191 IV

  • Experimental
    Selected Sarilumab IV Dose - Part B

    Participants will receive Sarilumab selected dose IV.

    Drug: Sarilumab, SAR153191 IV

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Assessment of Pharmacokinetic (PK) parameters of sarilumab in serum: area under the concentration-time curve [AUClast] for IV doses

    Area under the concentration versus time curve from time zero to time corresponding to the last measurable concentration, tlast.

    Time frame: from Baseline up to Week 6

  2. Part A: Assessment of PK parameters of sarilumab in serum: maximum concentration [Cmax] for IV doses

    Maximum concentration observed.

    Time frame: from Baseline up to Week 6

  3. Part B: Assessment of PK parameters of sarilumab in serum: plasma concentration at steady state (Ctrough ss)

    Concentration observed before treatment administration during repeated dosing at steady state.

    Time frame: from Baseline up to Week 30

Secondary outcomes

  1. Part A: Proportion of participants who experienced adverse events (AEs): treatment-emergent adverse events (TEAEs) up to the post-treatment EOS follow-up visit included

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent adverse events (TEAEs) are defined as AEs that developed, worsened or became serious during the treatment-emergent period.

    Time frame: From Baseline up to Week 32

  2. Part A: Proportion of participants who experienced potentially clinically significant abnormalities (PCSA) in clinical laboratory evaluations, vital signs, and electrocardiogram (ECG) parameters

    For laboratory variables (hematology, clinical biochemistry, urinalysis, serology and coagulation variables), the proportion of participants with at least 1 PCSA during the treatment-emergent period will be summarized. For vital signs (heart rate, systolic and diastolic blood pressure, and temperature) and ECG variables (heart rate, PR, QRS, QT and QTcF intervals), the proportion of participants with at least 1 PCSA during the treatment-emergent period will be summarized.

    Time frame: From Baseline up to Week 32

  3. Part A: Proportion of participants with injection site reactions (local tolerability assessments)

    Time frame: From Baseline up to Week 26

  4. Part B: Assessment of PK parameters of sarilumab in serum: maximum peak plasma drug concentration at steady state (Cmax ss)

    Maximum concentration observed at steady state.

    Time frame: from Baseline up to Week 30

  5. Part B: Area under the curve for the defined interval between doses (TAU) at steady state (AUC0-tau ss)

    Area under the concentration versus time curve calculated using the trapezoidal method during a dose interval (τ) at steady state.

    Time frame: from Baseline up to Week 30

  6. Part B: Proportion of participants who experienced adverse events (AEs): treatment-emergent adverse events (TEAEs) up to the post-treatment EOS follow-up visit included

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent adverse events (TEAEs) are defined as AEs that developed, worsened or became serious during the treatment-emergent period.

    Time frame: From Baseline up to Week 30

  7. Part B: Proportion of participants who experienced potentially clinically significant abnormalities (PCSA) in clinical laboratory test evaluations, vital signs, and electrocardiogram (ECG) parameters

    For laboratory variables (hematology, clinical biochemistry, urinalysis, serology and coagulation variables), the proportion of participants with at least 1 PCSA during the treatment-emergent period will be summarized. For vital signs (heart rate, systolic and diastolic blood pressure, and temperature) and ECG variables (heart rate, PR, QRS, QT and QTcF intervals), the proportion of participants with at least 1 PCSA during the treatment-emergent period will be summarized.

    Time frame: From Baseline up to Week 30

  8. Part B: Proportion of participants with injection site reactions (local tolerability assessments)

    Time frame: From Baseline up to Week 24

07

Study locations

12 of 12 sites recruiting
  • Veros Health- Site Number : 8400017
    Centennial, Colorado 80112, United States
    Recruiting
  • Clinical Research of West Florida - Phase I Unit- Site Number : 8400014
    Clearwater, Florida 33765, United States
    Recruiting
  • Sweet Hope Research Specialty- Site Number : 8400023
    Hialeah, Florida 33016, United States
    Recruiting
  • Encore Medical Research - Hollywood- Site Number : 8400010
    Hollywood, Florida 33024, United States
    Recruiting
  • Rheumwell Comprehensive Rheumatology- Site Number : 8400019
    Miami, Florida 33143, United States
    Recruiting
  • Integral Rheumatology and Immunology Specialists- Site Number : 8400018
    Plantation, Florida 33324, United States
    Recruiting
  • Encore Medical Research - Weston- Site Number : 8400011
    Weston, Florida 33331, United States
    Recruiting
  • Altoona Center for Clinical Research - Duncansville- Site Number : 8400007
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Texas Arthritis Center- Site Number : 8400021
    El Paso, Texas 79902, United States
    Recruiting
  • Prolato Clinical Research Center- Site Number : 8400006
    Houston, Texas 77054, United States
    Recruiting
  • Southwest Rheumatology Research- Site Number : 8400004
    Mesquite, Texas 75150, United States
    Recruiting
  • ClinRx Research - Plano- Site Number : 8400015
    Plano, Texas 75023, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.

Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 15, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Oct 26, 2028
CompletionEst.
Oct 26, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 United States)
  • Veros Health- Site Number : 8400017 · Centennial, United States
  • Clinical Research of West Florida - Phase I Unit- Site Number : 8400014 · Clearwater, United States
  • Sweet Hope Research Specialty- Site Number : 8400023 · Hialeah, United States
  • Rheumwell Comprehensive Rheumatology- Site Number : 8400019 · Miami, United States
  • Integral Rheumatology and Immunology Specialists- Site Number : 8400018 · Plantation, United States
  • Texas Arthritis Center- Site Number : 8400021 · El Paso, United States
  • Prolato Clinical Research Center- Site Number : 8400006 · Houston, United States
  • Southwest Rheumatology Research- Site Number : 8400004 · Mesquite, United States
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    8 sites added
    Show 8 added (8 United States)
    • Veros Health- Site Number : 8400017 · Centennial, United States
    • Clinical Research of West Florida - Phase I Unit- Site Number : 8400014 · Clearwater, United States
    • Sweet Hope Research Specialty- Site Number : 8400023 · Hialeah, United States
    • Rheumwell Comprehensive Rheumatology- Site Number : 8400019 · Miami, United States
    • Integral Rheumatology and Immunology Specialists- Site Number : 8400018 · Plantation, United States
    • Texas Arthritis Center- Site Number : 8400021 · El Paso, United States
    • Prolato Clinical Research Center- Site Number : 8400006 · Houston, United States
    • Southwest Rheumatology Research- Site Number : 8400004 · Mesquite, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07704580
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 2, 2026
Primary completion
Oct 26, 2028 (estimated)
Completion
Oct 26, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion